Sanofi has terminated the STAT6 phase one program, which it told Nurix about a couple of weeks ago, but the partnership and other STAT6 programs remain in place. Nurix has not yet received any data from Sanofi and has requested full reports.
NRIX · Nurix Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 32%
- Last earnings
- Jun 8, 2026
- Latest filing
- 10-Q · Oct 13
- Price history
- Jul 2020 to Nov 2026
Up next
Latest documents
On November 3, 2026, Nurix Therapeutics, Inc. said Sanofi S.A. will discontinue the Phase 1 first-in-human trial of SAR448272 and terminate the program, eliminating expected future development, regulatory and commercial milestone payments and royalties.
Nurix Therapeutics reported revenue of $673.1 million and net income of $549.8 million for the three months ended August 31, 2026, driven primarily by $653.2 million of Roche license revenue, and $1.1 billion in cash, cash equivalents and marketable securities.
Nurix Therapeutics posted $373.1 million net income for the nine months ended August 31, 2026, including $653.2 million of Roche license revenue. It held $1.1 billion in cash, cash equivalents and marketable securities and discontinued zelebrudomide in August 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRIX
this stock
Nurix Therapeutics, Inc.
|
$1.40B | -32.3% | +99.3% | 5.6 | 17.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 23
Sanofi has terminated the STAT6 phase one program, which it told Nurix about a couple of weeks ago, but the partnership and other STAT6 programs remain in place. Nurix has not yet received any data from Sanofi and has requested full reports.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRIX | -17.0% | -49.3% | -21.5% | -52.1% | -32.3% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -8.4% | -40.1% | -12.3% | -43.3% | -33.4% |